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Capsule summary: 
Monocytes from sepsis patients have mitochondrial DNA (mtDNA) depletion and immune 
deactivation. Here we find that THP-1 cell immune responses are impaired by experimentally 
depleting mtDNA, through dysregulated immune signalling, and rescued by interferon-γ 
treatment.  
To the Editor: 
Sepsis is a clinical syndrome with increasing incidence and mortality in which a systemic 
inflammatory response is triggered by infection. The clinical outcome of sepsis is primarily 
determined by the host response; in particular monocyte deactivation plays a key role in sepsis-
induced immune suppression and contributes to mortality1, 2. While the underlying mechanisms 
of monocyte deactivation are not understood, there is increasing evidence that mitochondrial 
dysfunction contributes to the pathogenesis of sepsis. Monocytes from sepsis patients have 
impaired mitochondrial respiration and depletion of mitochondrial DNA (mtDNA). These 
findings correlate with the severity of the illness3-6, but it is unclear whether the mitochondrial 
defects lead to the immune deactivation of blood monocytes, or occur simply as a consequence 
of sepsis. To address this issue, we studied the effects of reducing mtDNA levels on immune 
function in THP-1 cells, a human monocyte cell line. 
Treatment of THP-1 cells with 50ng/ml ethidium bromide for 8 weeks generated ρ0 cells 
lacking mtDNA (Fig.1a) without adverse effects on cell viability (Fig.S1a, methods in 
Supplementary Material). This completely suppressed mtDNA-encoded MT-CO1 protein levels 
and cytochrome c oxidase (COX) activity, without affecting nuclear-encoded SDHA expression or 
mitochondrial mass, measured by citrate synthase activity (Fig.S1b-d). The ρ0 cells had a 
blunted TNFα response to treatment with 100ng/ml lipopolysaccharide (LPS) for 4 hours 
(Fig.1b), consistent with monocyte deactivation. Repeating the experiments with short-
interfering RNA (siRNA, 30nM for 8 days) silencing the expression of mitochondrial 
transcription factor A (TFAM), a major component of the mitochondrial nucleoid that regulates 
mtDNA replication and gene expression (Fig. 1c), also suppressed mtDNA levels (Fig. 1d), 
reduced mitochondrial encoded proteins and oxygen consumption (Fig.S2c-d), and impaired the 
TNFα response to LPS (Fig.1e). While the TFAM siRNA-transfected THP-1 cells also had a 
reduced ability to phagocytose the Gram-negative bacterium Escherichia coli (Fig.S2e), there 
was not a global down-regulation of immunity as LPS-induced IL-8 production was unaltered 
(Fig.1e). The effects of mtDNA depletion were partially reversed after removal of the siRNA 
(Fig.1f-h,  S2f-h). 
To determine the mechanism linking mtDNA depletion with impaired immune function we 
performed whole transcriptome RNA-Seq before and after TFAM siRNA transfection (Fig.2a, 
Fig.S3). There were 1389 differential expressed genes in TFAM siRNA transfected THP-1 cells 
compared to controls (Fig.2a&b, Data File S1). Ingenuity Pathway Analysis (IPA®) of the gene 
ontology (GO) showed suppression of key innate immune signalling pathways, including 
interferon and TREM1 signalling (Fig. 2c, Fig. S3, Table S1). Following 4 hours treatment with 
100ng/ml LPS we observed a consistent up-regulation of inflammatory genes (log fold-change, 
LogFC> 1.5, Fig.3Sd). GO analysis showed that mtDNA depletion was associated with a 
significant down-regulation of multiple signalling pathways involved in pathogen recognition 
following exposure to LPS (Fig. 3Se-h, Table S2). Thus, the mtDNA depletion induced by TFAM 
siRNA blunts the immune response of THP-1 cells to LPS through known innate immune 
pathways. These findings were validated in independent experiments using reverse 
transcription quantitative PCR; mtDNA depletion blunted the LPS-induced up-regulation for key 
genes encoding cell surface receptors (TLR4, TREM1), pro-inflammatory cytokines (IL1B, TNF), 
interferon signalling molecules (IFIT1, IFITM1) and inflammatory mediators (MYD88, STAT1) 
(Fig.2d-g). TLR-4 expression, measured by flow cytometry, was significantly decreased 
following mtDNA depletion (Fig.2h), providing a potential explanation for the blunted immune 
response in THP-1 cells lacking mtDNA. 
Interferon gamma (IFN-γ) has been shown to reverse immune deactivation in septic 
monocytes7, and is a monocyte activator that stimulates TLR-4 expression through the 
interferon signalling pathways that are down-regulated with mtDNA depletion. Treating 
mtDNA-depleted THP-1 cells with 100ng/ml recombinant human IFN-γ in the final 24 hours of 
the 8 day siRNA transfection period had no adverse effects on THP-1 cell viability (Fig.S4a), but 
increased both  LPS-induced TNFα release (Fig.2i) and the capacity to phagocytose E. coli (Fig.2j, 
Fig.S4b). IFNγ treatment increased cell surface expression of TLR-4 in all experimental 
conditions (Fig.2k, Fig.S4c). 
Using two independent methods to induce mtDNA depletion, we show that mtDNA depletion 
can reversibly impair innate immune responses in THP-1 cells. In particular we identify a 
significant inhibition of TNFα production in response to LPS, thus reproducing the key 
phenotypic marker of immune deactivation in monocytes from patients with sepsis. The mtDNA 
depletion also inhibits interferon and pattern-recognition receptor-mediated signalling and 
decreased cell surface expression of TLR-4, changes that would fundamentally impair the 
responses of THP-1 cells to LPS and Gram negative bacteria. 
How can we explain the transcriptional changes we observed following mtDNA depletion? 
Mitochondrial abundance and mtDNA levels are tightly regulated in response to cellular 
energetic demands, and mtDNA depletion leads to a bioenergetic defect of OXPHOS and a 
reduction in ATP production. This could have several consequences. First, in cell lines from 
patients with rare inherited mtDNA mutations, the biochemical defect activates a retrograde 
signalling response from the mitochondria to the nucleus which alters the transcription of 
several genes known to be involved in immune activation. Linked to this there may be 
compensatory mitochondrial biogenesis, including the activation of peroxisome proliferator 
activated receptor (PPAR) signalling, similar to our observation in mtDNA-depleted THP-1 cells 
(Fig. 2c and 3Sh). Increased PPAR signalling has been associated with a shift to an anti-
inflammatory phenotype in animal models of sepsis8. Finally, the shift from oxidative to 
glycolytic metabolism in mtDNA-depleted THP-1 cells could produce changes in gene 
expression and immune phenotype. However, in macrophages, a shift to glycolytic metabolism 
has been associated with the adoption of a pro-inflammatory phenotype, with anti-
inflammatory macrophages rather having enhanced OXPHOS activity9.  
During severe sepsis, intense on-going mtDNA damage and mitochondrial dysfunction could 
overwhelm the capacity for mitochondrial biogenesis, leading to a gradual decline in mtDNA 
levels over time. Our data suggest that this may contribute to monocyte immune deactivation 
which is associated with adverse clinical outcomes and could be reversed by interferon-γ. Our 
observations were made on a transformed human monocyte line, and focused on TLR-4 specific 
mechanisms. If confirmed in human monocytes this would provide new opportunities to treat 
sepsis. 
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Figure Captions 
Fig. 1 Mitochondrial DNA depletion and reversible impaired immune functions in THP-1 cells 
(A-B) Treatment with 50ng/ml ethidium bromide (EtBr) for 8 weeks. ,. (A) mtDNA levels. (B) 
LPS-induced TNFα and IL-8 release . (C-E) Transfection with 30nM negative or TFAM siRNA for 
8 days.. (C) TFAM protein relative to β-actin. (D) mtDNA levels. (E) LPS-induced TNFα and IL-8 
release. (F-H) TFAM recovery 8 days after removal of TFAM siRNA. (F) TFAM protein relative β-
actin. (G) mtDNA levels. (H) LPS-induced TNFα and IL-8 release. All experiments are presented 
as mean ± standard deviation of 3-4 independent biological replicates. *p<0.05, **p<0.01, 
***p<0.001. 
Fig. 2 Transcriptomic response and immune dysfunction in TFAM siRNA-induced mtDNA 
depleted THP-1 cells is rescued by IFNγ treatment. (A) Hierarchiccal clustering for the 3000 
most expressed genes in all the samples used for RNAseq. (B) Volcano plot of differentially 
expressed genes between control and siRNA cells (dot size proportional to log-fold change 
(LogFC), >1.5 red (up-regulated), blue (down-regulated), green = the mitochondrial genes). (C). 
Altered canonical signalling pathways with siRNA. (D-G) qPCR validation of key genes. (H) Cell 
surface expression of TLR-4. (I) LPS-induced TNFα release after treatment with 100ng/ml IFNγ 
for the final 24 hours of the transfection period. (J) Phagocytosis of E. coli. (K)  Phagocytosis of  
E. coli.  (Abbreviations: iNOS –inducible nitric oxide synthase, IRF – interferon regulatory factor, 
PI3K – phoshoinositide-3-kinase,RIG1 – retinoic acid-inducible gene-1, TSP-1 – 
thrombospondin-1).  Data are presented as mean ± standard deviation of 3 independent 
biological replicates; *p<0.05, **p<0.01. 
Figure S1. Effects of mtDNA depletion on THP-1 cells. THP-1 cells were treated with 50ng/ml 
ethidium bromide (EtBr) for 8 weeks. (A) Cell viability. (B) Mitochondrial transcripts. (C) 
Mitochondrial proteins relative to β-actin. (D) Spectrophotometric measurements of isolated 
respiratory enzyme activity in cellular homogenates for complex IV (CIV) and citrate synthase 
(CS) activity. All experiments had three independent biological replicates and are presented as 
mean ± standard deviation; *p<0.05, **p<0.01, ***p<0.001. 
Figure S2. Mitochondrial DNA depletion and impaired immune functions and subsequent 
recovery in THP-1 cells following transfection with TFAM siRNA. (A-G) Transfection with TFAM 
siRNA. (A) TFAM proteins levels relative to β-actin during titration of TFAM siRNA, showing 
optimal knockdown of TFAM protein after transfection of THP-1 cells with 30nM siRNA for 8 
days. (B) Cell viability.  (C) Cell proliferation. . (D) The levels MT-CO1 and SDHA protein relative 
to β-actin.  (D) Oxygen consumption rates (OCR) for different aspects of mitochondrial 
respiration and respiratory profile. (E) Phagocytosis of  E. coli. (H-K) Recovery 8 days after 
removal of TFAM siRNA.; (F)Levels of the MT-CO1 and SDHA proteins relative to β-actin. (G) 
Oxygen consumption for different aspects of mitochondrial respiration . All experiments were 
carried out on 3-4 independent biological replicates and are presented as mean ± standard 
deviation; *p<0.05, **p<0.01, ***p<0.001. 
Figure S3: Canonical signalling pathways in mtDNA depleted THP-1 cells with and without LPS 
treatment. THP-1 cells were incubated in growth medium or transfected with 30nM of negative 
or TFAM siRNA for 8 days. After a final incubation with 100ng/ml LPS or medium for 4 hours, 
gene expression was assessed by RNA-Seq.  (A) Levels of transcripts for TFAM. (B) Principal 
components analysis plot. (C) The effect of transfection with TFAM siRNA on the Interferon (C) 
and TREM-1 (D) signalling pathways extracted from Ingenuity Pathway Analysis (IPA®,down-
regulated genes are highlighted in green and up-regulated genes are highlighted in red). (D) 
Volcano plot showing differentially expressed genes  in each experimental condition following 
treatment with LPS. (E) Volcano plot comparing the LPS response of TFAM siRNA-transfected 
cells to negative control siRNA transfected cells. (In the Volcano plots differentially expressed 
genes are highlighted in grey, genes with log fold change (LogFC) >1.5 are represented in red 
(up-regulated) or blue (down-regulated), while mitochondrial genes are highlighted in green. 
The size of the dots is proportional to the LogFC). (F) Gene Slim Ontology analysis carried out by 
Gene Ontology Consortium Fold Change enrichment for pathways with p<0.05. (G) IPA® 
analysis of the canonical signalling pathways significantly affected by the differential expression 
of genes after treatment with LPS in TFAM siRNA-transfected THP-1 cells compared to negative 
siRNA transfected cells. The data were filtered for Benjamini Hochberg Multiple Testing 
Correction p-value < 0.05 and z-score >±2. (Abbreviations: iNOS – inducible nitric oxide 
synthase, IRF – interferon regulatory factor, PI3K – phoshoinositide-3-kinase, RIG1 – retinoic 
acid-inducible gene-1, TSP-1 – thrombospondin-1). 
Figure S4: Treatment with interferon-γ increases TLR-4 expression and restores immune 
functions in THP-1 cells with mtDNA depletion following transfection with TFAM siRNA. THP-1 
cells were treated with 100ng/ml recombinant human IFN-γ or medium for the final 24 hours of 
an 8-day transfection with negative-control or TFAM siRNA, or incubation with growth medium. 
(A) Cell viability. (B) Phagocytosis of  E. coli. (C) Cell surface expression of TLR-4.  All 
experiments were carried out on 3 independent biological replicates and are presented as mean 
± standard deviation ; *p<0.05, **p<0.01, ***p<0.001. 
